ArticleMolecular and cellular biology1990
A novel pathway for alternative splicing: identification of an RNA intermediate that generates an alternative 5' splice donor site not present in the primary transcript of AMPD1.
Article in Molecular and cellular biology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Role of the HPRG Component of Striated Muscle AMP Deaminase in the Stability and Cellular Behaviour of the Enzyme.Biomolecules · 2018Review
- A novel 18-bp deletion mutation of the AMPD1 gene affects carcass traits in Qinchuan cattle.Molecular biology reports · 2010Article
- Regulation of rat AMP deaminase 3 (isoform C) by development and skeletal muscle fibre type.The Biochemical journal · 1997Article
- Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency.Journal of inherited metabolic disease · 1997Review
- GNAI3, GNAT2, AMPD2, GSTM are clustered in 120 kb of Chinese hamster chromosome 1q.Mammalian genome : official journal of the International Mammalian Genome Society · 1996Article
- Mammalian-heart adenylate deaminase: cross-species immunoanalysis of tissue distribution with a cardiac-directed antibody.Molecular and cellular biochemistry · 1995Article
- Skipping of multiple CFTR exons is not a result of single exon omissions.Human genetics · 1994Article
- Molecular biology of AMP deaminase deficiency.Pharmacy world & science : PWS · 1994Review
- Functionally distinct elements are required for expression of the AMPD1 gene in myocytes.Molecular and cellular biology · 1993Article
- Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect.The Journal of clinical investigation · 1993Article
- In vivo recognition of a vertebrate mini-exon as an exon-intron-exon unit.Molecular and cellular biology · 1993Article
- Molecular basis of AMP deaminase deficiency in skeletal muscle.Proceedings of the National Academy of Sciences of the United States of America · 1992Article
- Conversion of human interferon-beta from a secreted to a phosphatidylinositol anchored protein by fusion of a 17 amino acid sequence to its carboxyl terminus.Molecular and cellular biochemistry · 1992Article
- Exon recognition and nucleocytoplasmic partitioning determine AMPD1 alternative transcript production.Molecular and cellular biology · 1991Article
- New nucleotide sequence data on the EMBL File Server.Nucleic acids research · 1991Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
AMP deaminase (AMPD) is a central enzyme in eucaryotic energy metabolism, and tissue-specific as well as stage-specific isoforms are found in many vertebrates. This study demonstrates the AMPD1 gene product in rat is alternatively spliced. The second exon, a 12-base miniexon, was found to be excluded or included in a tissue-specific and stage-specific pattern. This example of cassette splicing utilizes a unique pathway through an RNA intermediate that generates an alternative 5' splice donor site at the point where exon 2 is ligated to exon 1. In the analogous intermediate of human AMPD1, the potential 5' splice donor site created at the boundary of exon 1 and exon 2 was a poor substrate for splicing because of differences in exon 2 sequences, and human AMPD1 was not alternatively spliced. These results demonstrate that in some cases alternative splicing may proceed through an RNA intermediate that generates an alternative splice donor site not present in the primary transcript. Discrimination between alternative 5' splice donor sites in the RNA intermediate of AMPD1 is apparently controlled by tissue-specific and stage-specific signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.